All In Biotech

Free tool

FAERS Monitor: Viberzi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206940 or its brand name (Viberzi, Eluxadoline). Reports on generic versions are filed under their own applications.

Reports

2,949

Serious

1,137

39% of reports

Hospitalization

567

Death reported

69

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use364
  • abdominal pain352
  • diarrhoea348
  • constipation283
  • pancreatitis278
  • nausea220
  • drug ineffective218
  • abdominal pain upper210
  • inappropriate schedule of drug administration162
  • vomiting137
  • fatigue118
  • dizziness108
  • wrong technique in product usage process108
  • pain105
  • incorrect dose administered90

Reports by year received

View as table
YearReports
20121
20153
2016837
2017724
2018266
2019318
2020184
2021116
202295
2023116
202492
2025120
202677

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,210 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pancreatitisSignal27837.733.79,871
inappropriate schedule of drug administrationSignal16216.314.02,310
abdominal painSignal35210.89.83,153
constipationSignal2839.38.32,098
abdominal pain upperSignal2107.36.41,142
diarrhoeaSignal3483.83.5753
wrong technique in product usage processSignal1083.83.2222
off label useSignal3643.02.7493
incorrect dose administeredSignal902.82.3104
vomitingSignal1372.11.877
nausea2202.01.7110
dizziness1081.51.321
pain1051.21.04
drug ineffective2181.21.06
fatigue1181.10.91

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.